Hormonal therapy may aid in reducing progression of early-stage prostate cancer during active surveillance

Cloud technology with futuristic hologram on smartwatch

For men with early-stage prostate cancer being managed by active surveillance, adding the hormonal agent apalutamide may lower the rate of positive biopsies during follow-up, suggests a preliminary clinical trial in The Journal of Urology, an Official Journal of the American Urological Association.

Jennifer Coolidge’s two chaotic speeches won the Golden Globes

Previous article

Creating a zoological specimen biobank

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News